Marie Louise Bønnelykke-Behrndtz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marie Louise Bønnelykke-Behrndtz has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anton Pottegård
Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark Odense Denmark
1 shared publication - Gete Toft
Aalborg Univ Hosp, Dept Plast Surg, Aalborg, Denmark
1 shared publication - Karoline Assifuah Kristjansen
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
1 shared publication Kasper Bruun Kristensen
Clinical Pharmacology, Pharmacy, and Environmental Medicine, Department of Public Health, University of Southern Denmark, Denmark
1 shared publicationKumanan Rune Nanthan
Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Aalborg University Hospital, Aalborg, Denmark
1 shared publication- Lene Birk-Sørensen
Aalborg Univ Hosp, Dept Plast Surg, Aalborg, Denmark
1 shared publication
Latest Publications
- Open Access
- 9 May 2025
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 151 (5) , 1-13
Repurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis
Purpose Drug repurposing may be an efficient strategy for identifying new cancer treatments. Tranexamic acid (TXA), an antifibrinolytic agent that affects the plasminogen-plasmin pathway, may have potential anticancer effects by influencing tumor cell proliferation, angiogenesis, inflammation, immune response, and tissue remodeling—all crucial processes contributing to tumor progression and metastasis. Objective Evaluate TXA’s anticancer effects across in vitro, animal, and clinical studies to assess its potential as a repurposed cancer drug. Methods The study was designed as a PRISMA-compliant systematic review and meta-analysis. The literature search was conducted in MEDLINE, EMBASE, Web of Science, and the Cochrane Library. In vitro, animal, and clinical studies investigating the anticancer effects of TXA or epsilon-aminocaproic acid (EACA) were included. Animal and clinical studies were critically appraised, and studies with a low risk of bias were included in the meta-analysis. Results Of 4367 identified records, 38 articles were included, collectively reporting findings from 41 in vitro studies, 34 animal studies (n = 843 animals), and seven clinical studies (n = 91 patients). The meta-analysis included nine animal studies and showed a tumor growth reduction in animals treated with TXA compared to controls with a standardized mean difference of – 1.0 (95%CI – 1.5; – 0.4) (p = 0.0002). Equivalently, the majority of in vitro studies reported reduced proliferation, viability, and invasiveness in TXA-exposed tumor cell lines. The clinical studies were considerably susceptible to bias, rendering any conclusions futile. Conclusions TXA shows promise as a repurposed cancer drug, revealing an overall reduction in tumor growth, viability, and invasiveness in animal and in vitro studies.
- 9 May 2025
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 151 (5) , 1-13
Open AccessRepurposing tranexamic acid as an anticancer drug: a systematic review and meta-analysis
Purpose Drug repurposing may be an efficient strategy for identifying new cancer treatments. Tranexamic acid (TXA), an antifibrinolytic agent that affects the plasminogen-plasmin pathway, may have potential anticancer effects by influencing tumor cell proliferation, angiogenesis, inflammation, immune response, and tissue remodeling—all crucial processes contributing to tumor progression and metastasis. Objective Evaluate TXA’s anticancer effects across in vitro, animal, and clinical studies to assess its potential as a repurposed cancer drug. Methods The study was designed as a PRISMA-compliant systematic review and meta-analysis. The literature search was conducted in MEDLINE, EMBASE, Web of Science, and the Cochrane Library. In vitro, animal, and clinical studies investigating the anticancer effects of TXA or epsilon-aminocaproic acid (EACA) were included. Animal and clinical studies were critically appraised, and studies with a low risk of bias were included in the meta-analysis. Results Of 4367 identified records, 38 articles were included, collectively reporting findings from 41 in vitro studies, 34 animal studies (n = 843 animals), and seven clinical studies (n = 91 patients). The meta-analysis included nine animal studies and showed a tumor growth reduction in animals treated with TXA compared to controls with a standardized mean difference of – 1.0 (95%CI – 1.5; – 0.4) (p = 0.0002). Equivalently, the majority of in vitro studies reported reduced proliferation, viability, and invasiveness in TXA-exposed tumor cell lines. The clinical studies were considerably susceptible to bias, rendering any conclusions futile. Conclusions TXA shows promise as a repurposed cancer drug, revealing an overall reduction in tumor growth, viability, and invasiveness in animal and in vitro studies.
- Open Access
- 1 November 2023
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 88, 235-242
Intra-abdominal pressure increases peri-operatively in patients undergoing deep inferior epigastric perforator flap reconstruction: A prospective study linking high intra-abdominal pressure to non-fatal lung embolism within one patient
- 1 November 2023
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 88, 235-242
Open AccessIntra-abdominal pressure increases peri-operatively in patients undergoing deep inferior epigastric perforator flap reconstruction: A prospective study linking high intra-abdominal pressure to non-fatal lung embolism within one patient
- 28 March 2023
- Published by Elsevier in Cancer Epidemiology
- Vol. 84, 102356
Tranexamic acid use is not associated with the risk of melanoma in Danish women: A nested case-control study using Danish health registries
- 28 March 2023
- Published by Elsevier in Cancer Epidemiology
- Vol. 84, 102356
Tranexamic acid use is not associated with the risk of melanoma in Danish women: A nested case-control study using Danish health registries